Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could pregnant women safely stop aspirin earlier? new trial investigates

NCT ID NCT06108947

Prevention Sponsor: St. Olavs Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This trial looks at whether pregnant women at high risk for preeclampsia can safely stop taking daily aspirin at 24-28 weeks instead of continuing until 36 weeks. Around 300 women will be randomly assigned to either stop or continue aspirin. The goal is to see if stopping early leads to the same low rate of preterm preeclampsia, potentially reducing medication burden.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aspirin (acetyl salicylic acid)
What this could lead to
If stopping aspirin early is safe, it could simplify care for many pregnant women at risk of preeclampsia, reducing unnecessary medication.
What could go wrong
This is a small, open-label trial, so results may not apply broadly. Stopping aspirin could increase preeclampsia risk in some women.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * 18 years or older * singleton live fetus with gestational age between 24 and 28 weeks * woman with high risk of preterm preeclampsia (\>1/100) in the first trimester screening * aspirin treatment with a dose 150 mg per day initiated at 16+6 weeks of gestation or less until randomization with adherence of at least 50% * low SFlt-1/PlGF ratio (Kryptor technology with cut-off 66) measured at 24-28 weeks Exclusion Criteria * not speaking Norwegian or English language * fetal anomalies diagnosed with ultrasound * informed consent for participation in the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pre-eclampsia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

preeclampsia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pre-eclampsia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • St. Olavs hospital

    RECRUITING

    Trondheim, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.